Press Room

DCAT Week 2026

Start
Monday, March 23, 2026
End
Thursday, March 26, 2026
Location: New York, United States

Hovione is excited to be once again attending the DCAT Week, the premier global event held annually in New York City for companies engaged in the Bio/Pharmaceutical Manufacturing Value Chain.

Meet the Hovione team. This is the perfect opportunity to speak with our experts and learn how we are supporting our customers worldwide in developing novel drugs that make a difference for patients. Get to know more about:

  • Our One-Site Solution

    Hovione can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.

     
  • Our Leadership in Spray Drying

    With the largest number of commercial projects, the best science and engineering, the largest capacity, and the most experienced team, Hovione can take your project from development to market like no one else.

     
  • Our Continuous Tableting Expertise

    For those aiming to go from development to manufacturing in record time with high quality and less variability, Hovione is Bridging Science and Manufacturing, allowing your drug product to be made faster and more efficiently today! Hovione can support Continuous Tableting based programs, including new products as well as batch to continuous conversions.

     
  • Our Innovative Platforms

    At Hovione we have a reputation for transforming nascent technologies into large-scale GMP-compliant platforms by building strategic partnerships with our customers and technology partners. We look forward to seeing you to share some exciting news.

 

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026